


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A compound of Formula (I) or a salt, pro-drug, or solvate thereof:




Formula (I)

wherein:

A is phenyl or a 5- or 6-membered heteroaryl ring, where A is unsubstituted or substituted by with 1 or 2 groups independently selected from R³;
R¹ is selected from hydrogen and methyl;
R² is selected from hydrogen and methyl; and
R³ is selected from methyl, methoxy, fluoro, chloro and cyano;
with the proviso that at least one of R¹ and R² is methyl;
or a salt, pro-drug or solvate thereof.


Claim 2 (currently amended): A compound of Formula (I) or a salt, pro-drug, or solvate thereof, as claimed in Claim 1, wherein R¹ is methyl.

Claim 3 (currently amended): A compound of Formula (Ia), as claimed in Claim 1
~~or Claim 2, which is a compound of Formula (Ia), or a salt, pro-drug, or solvate thereof;~~
~~wherein A and R² are as defined in Claim 1~~




Formula (Ia)

Claim 4 (currently amended): A compound of Formula (Ia) (Ib), as claimed in Claim 3, ~~which is a compound of Formula (Ib)~~, or a salt, pro-drug, or solvate thereof:



Formula (Ib)

Claim 5 (~~original~~ currently amended): A compound of Formula (Ia) (Ic), as claimed in Claim 3, ~~which is a compound of Formula (Ie)~~, or a salt, pro-drug, or solvate thereof:



Formula (Ic)


wherein:

A' is a 5- or 6-membered heteroaryl ring.

Claim 6 (currently amended): A compound of Formula (I), (Ia), (Ib) or (Ie) as claimed in any one of Claims 1 to 5, or a salt, pro-drug, or solvate thereof, wherein R² is hydrogen, or a salt, pro-drug or solvate thereof.

Claim 7 (currently amended): A compound of Formula (I) (Ie) as claimed in Claim

| 1, which is a compound of Formula (Ie); or a salt, pro-drug, or solvate thereof:



Formula (Ie)

wherein:

A is selected from phenyl, thienyl and furanyl;

A is optionally substituted with methyl, methoxy, chloro or fluoro;

| R¹ is selected from hydrogen and methyl; and

R² is selected from hydrogen and methyl;

with the proviso that at least one of R¹ and R² is methyl.

Claim 8 (original): A compound of Formula (I) as claimed in Claim 1, selected from:

6-{3-[(1S)-1-methyl-2-phenylethoxy]-5-[(1S)-2-methoxy-

1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-furan-2-ylethoxy]-5-[(1S)-2-methoxy-

1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-(2-methoxyphenyl)ethoxy]-5-[(1S)-2-methoxy-

1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-thien-2-ylethoxy]-5-[(1S)-2-methoxy-

1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-(5-chlorothien-2-yl)ethoxy]-5-[(1S)-2-methoxy-

1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-thien-3-ylethoxy]-5-[(1S)-2-methoxy-

1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-(5-methylfuran-2-yl)ethoxy]-5-[(1S)-2-methoxy-

1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-{4-fluorophenyl}ethoxy]-5-[(1S)-2-methoxy-

1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(2S)-2-methyl-2-phenylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-

benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(2R)-2-methyl-2-phenylethoxy]-5-[(1S)-2-methoxy-
1-methylethoxy]-benzoylamino} -3-pyridine carboxylic acid; and
6-{3-[(1S)-1-methyl-2-{2-chlorophenyl}ethoxy]-5-[(1S)-2-methoxy-
1-methylethoxy]- benzoylamino}-3-pyridine carboxylic acid;
6-{3-[(1S)-1-methyl-2-{3,5-difluorophenyl}ethoxy]-5-[(1S)-2-methoxy-
1-methylethoxy]- benzoylamino}-3-pyridine carboxylic acid;
6-{3-[(1S)-1-methyl-2-{3-fluorophenyl}ethoxy]-5-[(1S)-2-methoxy-
1-methylethoxy]- benzoylamino}-3-pyridine carboxylic acid;
6-{3-[(1S)-1-methyl-2-(5-methylthiophen-2-yl)ethoxy]-5-[(1S)-2-methoxy-
1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
6-{3-[(1S)-1-methyl-2-{3-methoxyphenyl}ethoxy]-5-[(1S)-2-methoxy-
1-methylethoxy]- benzoylamino}-3-pyridine carboxylic acid;
6-{3-[(1S)-1-methyl-2-{2-methylphenyl}ethoxy]-5-[(1S)-2-methoxy-
1-methylethoxy]- benzoylamino}-3-pyridine carboxylic acid;
6-{3-[(1S)-1-methyl-2-{4-methoxyphenyl}ethoxy]-5-[(1S)-2-methoxy-
1-methylethoxy]- benzoylamino}-3-pyridine carboxylic acid; and
6-{3-[(1S)-1-methyl-2-(5-chlorofuran-2-yl)ethoxy]-5-[(1S)-2-methoxy-
1-methylethoxy]- benzoylamino}-3-pyridine carboxylic acid;
or a salt, pro-drug or solvate thereof.

Claim 9 (currently amended): A pharmaceutical composition comprising a compound of Formula (I) as claimed in any one of Claims Claim 1 to 8, or a salt, solvate or pro-drug, or solvate thereof, together with a pharmaceutically-acceptable diluent or carrier.

Claims 10 and 11 (canceled)

Claim 12 (currently amended): A method of treating GLK mediated diseases, especially diabetes, by comprising administering an effective amount of a compound of Formula (I), as claimed in any one of Claims Claim 1 to 8, or a salt, solvate or pro-drug, or solvate thereof, to a mammal in need of such treatment.


Claims 13 and 14 (canceled)

Claim 15 (currently amended): A method for the combined treatment of obesity and diabetes by comprising administering an effective amount of a compound of Formula (I), as claimed in any one of Claims Claim 1 to 8, or a salt, solvate or pro-drug, or solvate thereof, to a mammal in need of such treatment.

Claim 16 (currently amended): A method for the treatment of obesity by comprising administering an effective amount of a compound of Formula (I), as claimed in any one of Claims Claim 1 to 8, or a salt, solvate or pro-drug, or solvate thereof, to a mammal in need of such treatment.

Claim 17 (currently amended): A process for the preparation of a compound of Formula (I) as claimed in Claim 1, a salt, pro-drug, or solvate thereof which comprises:

(a) reaction of reacting an acid of Formula (IIIa) or activated derivative thereof with a compound of Formula (IIIb),




Formula (IIIa)

Formula (IIIb),

wherein P¹ is H or a protecting group; or


(b) de protection of deprotecting a compound of Formula (IIIc),




Formula (IIIc)

wherein P¹ is a protecting group; or

(c) reaction of reacting a compound of Formula (IIId) with a compound of Formula (IIIe),




Formula (IIId)




Formula (IIIe)

wherein X^1 is a leaving group and X^2 is a hydroxyl group, or X^1 is a hydroxyl group and X^2 is a leaving group; and wherein P^1 is a protecting group; or

- | (d) reaction of reacting a compound of Formula (IIIf) with a compound of Formula (IIIg)




Formula (IIIf)




Formula (IIIg)

wherein X^3 is a leaving group and X^4 is a hydroxyl group, or X^3 is a hydroxyl group and X^4 is a leaving group; or

- | (e) reaction of reacting a compound of Formula (IIIh) with a compound of Formula (IIIi),



Formula (IIIh)



Formula (IIIi);

wherein X^5 is a leaving group and wherein P^1 is H or a protecting group;

and thereafter, if necessary:

- i) converting a compound of Formula (I) into another compound of Formula (I);
- ii) removing any protecting groups; and/or
- iii) forming a salt, pro-drug, or solvate thereof.

Claim 18 (new): A method for the treatment of diabetes comprising administering an effective amount of a compound of Formula (I), as claimed in claim 1, or a salt, pro-drug, or solvate thereof, to a mammal in need of such treatment.